ReviewNutrients2025
The Changes in Plasmalogens: Chemical Diversity and Nutritional Implications-A Narrative Review.
Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Borate-Bridged Protolipids: A Prebiotic Route to Abiotic Membranes.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Plasmalogens, as natural dietary lipids, are a unique class of glycerophospholipids with distinct structural and functional properties. They are unstable due to the vinyl ether linkage and the unsaturated fatty chains. Hence, plasmalogen changes are closely connected to their beneficial bioactivities and health-related applications. This narrative review focuses on their structural modifications, particularly oxidation of the vinyl-ether and sn-2 acyl chains, enzymatic degradation, and molecular remodeling. The oxidative susceptibility of plasmalogens renders them particularly vulnerable under inflammatory or oxidative stress, contributing to a measurable reduction in total plasmalogen content. Plasmalogen deficiency has been observed in various diseases and applied in clinical applications, including physiological and a variety of pathological conditions. Moreover, plasmalogens have been recognized as not only disease biomarkers but also therapeutic targets. In addition, recent findings in nutrition were discussed, aiming to find that underutilized animal byproducts and microbial lipids are promising new sources of plasmalogens. To conclude, it is crucial to establish practical dynamic monitoring systems of plasmalogens for health promotion and disease prevention interventions. Integrating biochemical pathways, clinical diagnosis, and nutritional interventions remains to be clarified.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.